CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Benitec Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Benitec Biopharma Inc
Level 14, 114 William St
Phone: +61 386927222p:+61 386927222 MELBOURNE, VIC  3000  Australia Ticker: BNTCBNTC

This company ceased filing statements with the SEC on 4/27/2020.

Business Summary
Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20196/30/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board Jerel A.Banks 6/14/2018 10/26/2016
Chief Executive Officer, Company Secretary GregoryWest 8/10/2016 5/26/2011
Chief Financial Officer BryanDulhunty 7/1/2016 7/1/2016
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Benitec Ltd
Benitec Ltd.
BLT
4 additional Business Names available in full report.

General Information
Number of Employees: 13 (As of 6/30/2014)
Outstanding Shares: 321,287,046 (As of 12/31/2019)
Shareholders: 3,571
Stock Exchange: NASD
Fax Number: +61 399669923


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, June 02, 2020